Pilot study of the combination of capecitabine plus oxaliplatin as adjuvant therapy for patients with stage III and high risk stage II colon cancer

被引：0
|
作者：
Olier, C. [1 ]
Reyna, C. [1 ]
Aramendia, J. M. [1 ]
Rodriguez, J. [1 ]
Viudez, A. [1 ]
Chopitea, A. [1 ]
Garcia-Foncillas, J. [1 ]
机构：
[1] Univ Navarra Clin, Pamplona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.15093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15093
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data
    Amlani, Adam
    Kumar, Aalok
    Ruan, Jenny Y.
    Cheung, Winson Y.
    CANCER MEDICINE, 2016, 5 (08): : 1776 - 1782
  • [42] The Surgeon and Adjuvant Therapy for Stage II Colon Cancer
    David Ota
    Heidi Nelson
    Annals of Surgical Oncology, 2007, 14 : 272 - 273
  • [43] The surgeon and adjuvant therapy for stage II colon cancer
    Ota, David
    Nelson, Heidi
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 272 - 273
  • [44] Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer
    Brungs, Daniel
    Aghmesheh, Morteza
    de Souza, Paul
    Carolan, Martin
    Clingan, Philip
    Rose, June
    Ranson, Marie
    CLINICAL COLORECTAL CANCER, 2018, 17 (03) : E549 - E555
  • [45] Pharmacoeconomic analysis of capecitabine in adjuvant treatment of stage III colon cancer in Taiwan
    Hsu, T. C.
    Chen, H. H.
    Chen, L. T.
    Changchien, C. R.
    Liu, M. C.
    Wang, H. M.
    Yang, L.
    VALUE IN HEALTH, 2007, 10 (03) : A11 - A12
  • [46] KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX
    Dae-Won Lee
    Kyung Ju Kim
    Sae-Won Han
    Hyun Jung Lee
    Ye Young Rhee
    Jeong Mo Bae
    Nam-Yun Cho
    Kyung-Hun Lee
    Tae-Yong Kim
    Do-Youn Oh
    Seock-Ah Im
    Yung-Jue Bang
    Seung-Yong Jeong
    Kyu Joo Park
    Jae-Gahb Park
    Gyeong Hoon Kang
    Tae-You Kim
    Annals of Surgical Oncology, 2015, 22 : 187 - 194
  • [47] KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX
    Lee, Dae-Won
    Kim, Kyung Ju
    Han, Sae-Won
    Lee, Hyun Jung
    Rhee, Ye Young
    Bae, Jeong Mo
    Cho, Nam-Yun
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Oh, Do-Youn
    Im, Seock-Ah
    Bang, Yung-Jue
    Jeong, Seung-Yong
    Park, Kyu Joo
    Park, Jae-Gahb
    Kang, Gyeong Hoon
    Kim, Tae-You
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (01) : 187 - 194
  • [48] Cost-effectiveness of adjuvant chemotherapy for patients with high-risk stage II and stage III colon cancer in South Africa.
    Pumpalova, Yoanna S.
    Rogers, Alexandra M.
    Tan, Sarah Xinhui
    Herbst, Candice-Lee
    Ruff, Paul
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Adjuvant chemotherapy for stage III colon cancer patients
    Balakrishnan, L
    EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1496 - 1496
  • [50] Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
    Chen, Xin
    Tu, Junhao
    Xu, Xiaolan
    Gu, Wen
    Qin, Lei
    Qian, Haixin
    Jia, Zhenyu
    Ma, Chuntao
    Xu, Yinkai
    FRONTIERS IN ONCOLOGY, 2022, 12
12345